These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23396586)

  • 21. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.
    Fan X; Brezski RJ; Fa M; Deng H; Oberholtzer A; Gonzalez A; Dubinsky WP; Strohl WR; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2012 Aug; 14(4):R116. PubMed ID: 22873525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
    Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
    FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.
    Ma Y; Xiang D; Sun J; Ding C; Liu M; Hu X; Li G; Kloecker G; Zhang HG; Yan J
    J Immunol; 2013 Jun; 190(11):5588-99. PubMed ID: 23630363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
    Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
    J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
    Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
    Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells.
    Richards JO; Albers AJ; Smith TS; Tjoe JA
    Cancer Immunol Immunother; 2016 Nov; 65(11):1325-1335. PubMed ID: 27573917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
    Treffers LW; van Houdt M; Bruggeman CW; Heineke MH; Zhao XW; van der Heijden J; Nagelkerke SQ; Verkuijlen PJJH; Geissler J; Lissenberg-Thunnissen S; Valerius T; Peipp M; Franke K; van Bruggen R; Kuijpers TW; van Egmond M; Vidarsson G; Matlung HL; van den Berg TK
    Front Immunol; 2018; 9():3124. PubMed ID: 30761158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
    Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel therapeutic strategy to rescue the immune effector function of proteolytically inactivated cancer therapeutic antibodies.
    Fan X; Brezski RJ; Deng H; Dhupkar PM; Shi Y; Gonzalez A; Zhang S; Rycyzyn M; Strohl WR; Jordan RE; Zhang N; An Z
    Mol Cancer Ther; 2015 Mar; 14(3):681-91. PubMed ID: 25552368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of internalizing antibodies to tumor antigens from phage libraries.
    Zhou Y; Marks JD
    Methods Enzymol; 2012; 502():43-66. PubMed ID: 22208981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative functional characterization of canine IgG subclasses.
    Bergeron LM; McCandless EE; Dunham S; Dunkle B; Zhu Y; Shelly J; Lightle S; Gonzales A; Bainbridge G
    Vet Immunol Immunopathol; 2014 Jan; 157(1-2):31-41. PubMed ID: 24268690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.
    Rudnick SI; Lou J; Shaller CC; Tang Y; Klein-Szanto AJ; Weiner LM; Marks JD; Adams GP
    Cancer Res; 2011 Mar; 71(6):2250-9. PubMed ID: 21406401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
    Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
    Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
    Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.